Sorilux
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Analyst Outlook
Following its 2010 launch, Sorilux (calcipotriene; Stiefel/GlaxoSmithKline) has experienced slow
uptake in the psoriasis market, despite having the financial support of GlaxoSmithKline. This comes as
no surprise as the US psoriasis market is saturated with several types of established calcipotriene
formulations, limiting Sorilux’s uptake. Even though Sorilux received further US approval to include
the topical treatment of scalp psoriasis in September 2012, Datamonitor Healthcare believes that the
brand will struggle to compete with Leo Pharma’s scalp formulation products with which physicians
have extensive clinical experience.
Drug Overview
Sorilux is a vitamin D3 analog that works by controlling the overproduction of skin cells in patients
affected by psoriasis. However, the exact mechanism of action contributing to its clinical efficacy in
the treatment of psoriasis is unknown.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Sorilux : Psoriasis
LIST OF FIGURES
8 Figure 1: Sorilux for psoriasis – SWOT analysis
LIST OF TABLES
4 Table 1: Sorilux drug profile
6 Table 2: Sorilux pivotal trial data in psoriasis
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Pneumococcal Vaccines KOL Interview 
Sign up to the